Results 1 to 10 of about 3,304 (220)

Case Report: Carbonic anhydrase inhibitor brinzolamide dramatically improved the morphology and also function of a patient with RS1 mutation [PDF]

Frontiers in Pharmacology
X-linked retinoschisis (XLRS) is an inherited retinal disease caused by mutations in the RS1 gene, which encodes retinoschisin, a protein essential for maintaining the retinal structure during development.
Yue Ren, Yue Ren, Shu Liu, Shu Liu, Jia Rong, Di Wang, Miao Diao, Yaqi Zhang, Shimiao Tian, Mingxin Shang, Chuqiao Song, Yan Guan, Zhuoshi Wang, Zhuoshi Wang, Jijing Pang, Jijing Pang, Jijing Pang   +16 more
doaj   +2 more sources

Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2019
Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but the efficacy was controversial.
Yuanzhi Liu, Junyi Zhao, Junyi Zhao, Xiaoyan Zhong, Qiming Wei, Yilan Huang   +5 more
exaly   +3 more sources

Effect of topical brinzolamide on visual function and waveform in patients of infantile nystagmus syndrome: A randomized control trial [PDF]

Indian Journal of Ophthalmology
Purpose: To evaluate the effect of topical carbonic anhydrase inhibitor (brinzolamide) versus placebo on visual function and waveforms in infantile nystagmus syndrome (INS). Design: Prospective, placebo-controlled, double-blind, cross-over study. Methods:
Bhupendra Yadav, Rohit Saxena, Rebika Dhiman, Kanwal P. Kochhar, Ashlesh Patil, Pradeep Sharma, Ramanjit Sihota, Radhika Tandon   +7 more
doaj   +2 more sources

Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy

Drug Delivery, 2020
Co-delivery nanoparticles with characteristics of intracellular precision release drug have been generally accepted as an effective therapeutic strategy for eye diseases.
Tingting Li, Ye Wang, Jiahao Chen, Xiaoshu Gao, Siqi Pan, Yu Su, Xinrong Zhou   +6 more
exaly   +2 more sources

Sustained intraocular pressure-lowering effect and biocompatibility of a single subconjunctival administration of hydrogel-encapsulated nano-brinzolamide [PDF]

Journal of Materials Science: Materials in Medicine
Brinzolamide is a widely used treatment for glaucoma, but its effectiveness relies on at least twice-daily dosing, which can be challenging for patient adherence.
Jiahao Xu, Linyu Long, Xiaoyu Zhou, Xinyue Zhang, Li Liao, Dan Ji, Xuanchu Duan   +6 more
doaj   +2 more sources

Stressing the limits of capillary blood in anti-doping analysis: perspectives on alkylamine-like stimulants and carbonic anhydrase II inhibitors in result management [PDF]

Frontiers in Sports and Active Living
The establishment of an anti-doping rule violation extends beyond the mere detection of a prohibited substance. Current interpretation criteria rely primarily on urinary concentration estimates, which may be misleading due to high interindividual ...
Isabelle Karine da Costa Nunes, Mariana Vaz Carneiro, Felipe Alves Gomes de Oliveira, Ana Carolina Dudenhoeffer Carneiro, Carina de Souza Anselmo, Christian Farias Trajano, Monica Costa Padilha, Henrique Marcelo Gualberto Pereira   +7 more
doaj   +2 more sources

Intraocular pressure is a promising target for myopia control [PDF]

Journal of Translational Medicine
Background Myopia presents a noteworthy global health concern, urging exploration of innovative treatments. The role of intraocular pressure (IOP) in regulating the progression of myopia has been controversial.
Peiyuan Wang, Kangjie Kong, Jiaxuan Jiang, Jingwen Jiang, Zihong Xie, Fengbin Lin, Yunhe Song, Xiuli Fang, Ling Jin, Fei Li, Wei Wang, Shaolin Du, Zhuoxing Shi, Junwen Zeng, Xiulan Zhang, Shida Chen, for the Glaucoma Suspects with High Myopia Study Group   +16 more
doaj   +2 more sources

A comparative study on the efficacy of brinzolamide/timolol versus brinzolamide/brimonidine fixed drug combinations in primary open-angle glaucoma [PDF]

Future Journal of Pharmaceutical Sciences, 2020
Background To compare the efficacy of brinzolamide 1%/timolol 0.5% fixed drug combination (BTFC) with brinzolamide 1%/brimonidine 0.2% fixed drug combination (BBFC) among the patients with primary open-angle glaucoma (POAG).
Sudeepthi Padala, Ramam Sripada, Srivalli Bhaskari Padmavathi Gundabattula, Krishna Jyothi Tadi, Prabhakar Rao Nallamothula, Farzaneh Raveshi, Dasaratha Dhanaraju Magharla   +6 more
doaj   +4 more sources

Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment [PDF]

Materials Today Bio
Glaucoma ranked second among the causes of blindness globally, necessitates the development of novel and effective therapeutic strategy. Anti-glaucoma eye drops as a topical dosage form are still considered as a method of choice for glaucoma treatment ...
Haroon Iqbal, Dengming Zhou, Anam Razzaq, Haiyang Zhang, Run Xiao, Fu Lin, Yuanbo Liang   +6 more
doaj   +2 more sources

Whiter and Greener RP-HPLC Method for Simultaneous Determination of Dorzolamide, Brinzolamide, and Timolol Using Isopropanol as a Sustainable Organic Solvent in the Mobile Phase [PDF]

Separations
A sustainable reversed-phase chromatographic method has been developed and validated for the simultaneous determination of three active pharmaceutical ingredients, dorzolamide, brinzolamide, and timolol, used to treat glaucoma.
Sami El Deeb, Khalid Abdelsamad, Maria Kristina Parr   +2 more
doaj   +3 more sources